Abstract: The invention relates to compounds that are heterocyclic derivatives of dipeptides and dipeptides mimetics and pharmaceutically acceptable salts thereof.

Abstract: A latching device (1) particularly for installation such as swimming pool gates may have an automatic magnetic latch with a child resistant device to control access. The child resistant device may include an operating handle (10) at an elevated location to be out of the reach of the child and an alternative operating device (11) is provided at a lower location with child resistance provided typically by a push button arrangement (12) acting through a cam and cam follower to raise a latching arm (3) against the biasing to the latching position. A simple pronged key (16) for a pushing action can be provided, but another aspect consists in a mechanically actuatable key pad (20) which can readily be operated by an adult even in a wheelchair, but which is resistant to child actuation. For example, a selected two of eight buttons may be required to be depressed to permit the key to actuate the push button.

Abstract: The present invention provides a blade driving mechanism for a table saw, wherein the table saw comprises a main frame and a saw blade mounted to and driven by the blade driving mechanism, and the blade driving mechanism comprises an electrical motor mounted to the main frame, with the motor being capable of sliding with respect to the main frame; a belt driving system for transferring the rotation of an output shaft of the motor to the saw blade; a center-distance setting means connected between the motor and the saw blade, for adjustably setting the center-to-center distance between the motor and the saw blade; and a saw-blade height adjusting device being operable to adjust the height of the of the saw blade.

Abstract: A process for the preparation of inhibitors of HMG-CoA reductase, such as simvastatin, from 4-silyloxytetrahydropyran-2-ones with triethylamine trihydrofluoride being used as the desilylation reagent is described. The reaction is performed in organic solvents, a mixture thereof or without solvents. It is characteristic of this reaction that no additional impurities are obtained and that it takes place without the use of additional catalysts and with low excesses of the reagent.

Abstract: Lovastatin, pravastatin, simvastatin, mevastatin, atorvastatin, fluvastatin and cervastatin and derivatives and analogs thereof are known as HMG-CoA reductase inhibitors and are used as antihypercholesterolemic agents. The majority of them are produced by fermentation using microorganisms of different species identified as species belonging to Aspergillus, Monascus, Nocardia, Amycolatopsis, Mucor or Penicillium genus, some are obtained by treating the fermentation products using the methods of chemical synthesis (simvastatin) or they are the products of total chemical synthesis (fluvastatin, atorvastatin and cervastatin). The present invention relates to a crystalline form of the sodium salt of pravastatin, which is known by the chemical name 1-naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro-?,?,6-trihydroxy-2-methyl-8-(2-methyl-1-oxobutoxy)-, mono sodium salt, which is useful as a pharmaceutical substance.

Abstract: Lovastatin, pravastatin, simvastatin, mevastatin, atorvastatin, fluvastatin and cervastatin and derivatives and analogs thereof are known as HMG-CoA reductase inhibitors and are used as antihypercholesterolemic agents. The majority of them are produced by fermentation using microorganisms of different species identified as species belonging to an Aspergillus, Monascus, Nocardia, Amycolatopsis, Mucor, or Penicillium genus, some are obtained by treating the fermentation products using the methods of chemical synthesis (simvastatin) or they are the products of total chemical synthesis (fluvastatin, atorvastatin and cervastatin). The present invention relates to a crystalline form of the sodium salt of pravastatin, which is known by the chemical name 1-naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro-?,?,6-trihydroxy-2-methyl-8-(2-methyl-1-oxobutoxy)-, mono sodium salt, which is useful as a pharmaceutical substance.

Abstract: Non-crystalline, in particular amorphous, pharmaceutically acceptable atorvastatin salts, especially the calcium salt, are prepared from atorvastatin lactone or from a compound of formula (I) where A denotes a common protecting group or separate protecting groups for the two hydroxy groups, and B denotes a carboxylic acid protecting group, without the need of prior formation of atorvastatin lactone, the crystalline form of the atorvastatin salt, or a mixture of amorphous and crystalline forms of the atorvastatin salt. Pharmaceutical formulations are prepared from these salts.

Abstract: The invention relates an electric sharpener, comprises a main frame, a main shaft, a motor, a transmission wheel, a grinding stone, and an electric control circuit. The motor is mounted on an angular frame which in turn is mounted on the main frame. The transmission wheel is fixed to an end of the main shaft, and the output shaft of the motor is tightly pressed against the periphery of the transmission wheel so as to drive it. A tool rest is fixed onto the main frame in a vertical or horizontal mounting orientation. A water vessel is fixed to the main frame, and the lower portion of the grinding stone dips into the water contained in the water vessel. Special clamps and attachments for grinding different tools are provided. The electric sharpener can be used for grinding various woodworking or household tools.

Abstract: The present invention provides a wheel-immobilizing device that does not require holes or indentations in the wheel in order for the device to be secured around the wheel or caster being immobilized. Additionally, a wheel-immobilizing device according to the invention is configured such that it may be placed on the ground in front of a cabinet, and the cabinet simply rolled into position with one of its casters between side walls of the device. The wheel-immobilizing device is then secured around the caster by passing a cross member or, in some embodiments, two cross members through the side walls on either side of the caster stem and then securing the cross member or members in position, thereby locking the wheel-immobilizing device to the caster of the cabinet and hampering rolling movement of the cabinet.

Abstract: Atorvastatin calcium, the substance known by the chemical name (R—(R*,R*))-2-(4-fluorophenyl)-?, ?-dihydroxy-5-(1-methylethyl)-3-phenyl-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoic acid hemi calcium salt is known as HMG-CoA reductase inhibitor and is used as an antihypercholesterolemic agent. Atorvastatin in the pharmaceutical compositions available in the market, is usually prepared as its calcium salt since it enables atorvastatin to be conveniently formulated in the pharmaceutical formulations, for example, in tablets, capsules, powders and the like for oral administration. Atorvastatin calcium can exist in an amorphous form or in one of the at least four known crystalline forms (Form I, Form II, Form III and Form IV). Atorvastatin calcium is the substance which is sparingly soluble in water, with pKa 4,5, and it has been found that the crystalline forms are less soluble than the amorphous form, which may cause problems in bioavailability of atorvastatin in the body.

Abstract: Display apparatus comprises a support frame having elongate frame members (1) pivotally interconnected at nodes (2) and at their crossing mid points so that the apparatus is capable of being transformed between a compact condition for storage or transport and an erected condition in which display panels (3) can be attached to the frame. The nodes (2) are arranged in vertically spaced groups and the uppermost node (2) of each group carries a reel (9) in which is wound a metal tape (8) withdrawable from the reel (9) to support the display panels (3) on the frame by magnetic attraction.

Abstract: The invention provides an improved process for preparing Olanzapine as well as intermediates therefor.

Abstract: The present invention relates to a novel solid pharmaceutical formulation containing lovastatin and simvastatin, respectively, with a particle size D(0.9) between 15 and 100 ?m and a specific particle surface area between 1 and 4 m2/g, and to the process for its preparation. The present invention also relates to the method for production of lovastatin and simvastatin with the size of crystals which are suitable for the preparation of the pharmaceutical formulation of the present invention. The novel solid pharmaceutical formulation is useful for treating hypercholesterolemia and hyperlipidemia.